These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19289350)

  • 1. Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics.
    Ried LD; Brumback B; Bengtson MA; Garman PM; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2009; 49(2):223-31. PubMed ID: 19289350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.
    Hsu C; Ried LD; Bengtson MA; Garman PM; McConkey JR; Rahnavard F
    J Am Pharm Assoc (2003); 2008; 48(3):393-400. PubMed ID: 18595825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders.
    Ried LD; McConkey JR; Bengtson MA; Garman PM; Hsu C; Rahnavard F
    J Am Pharm Assoc (2003); 2007; 47(2):156-64. PubMed ID: 17510002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
    Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
    Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM
    BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.
    Sugai T; Suzuki Y; Fukui N; Ono S; Watanabe J; Tsuneyama N; Someya T
    J Clin Psychopharmacol; 2012 Jun; 32(3):390-3. PubMed ID: 22544005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
    Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
    Hardy TA; Henry RR; Forrester TD; Kryzhanovskaya LA; Campbell GM; Marks DM; Mudaliar S
    Diabetes Obes Metab; 2011 Aug; 13(8):726-35. PubMed ID: 21435142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.
    Guo Z; L'italien GJ; Jing Y; Baker RA; Forbes RA; Hebden T; Kim E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1326-32. PubMed ID: 21515328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
    Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
    Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
    Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
    J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
    Vuk A; Kuzman MR; Baretic M; Osvatic MM
    Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
    Lee NY; Kim SH; Jung DC; Kim EY; Yu HY; Sung KH; Kang UG; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1273-8. PubMed ID: 21513765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
    Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
    J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.